Show Summary Details
Page of

Randomized controlled trial evidence for gabapentin in post-herpetic neuralgia 

Randomized controlled trial evidence for gabapentin in post-herpetic neuralgia
Chapter:
Randomized controlled trial evidence for gabapentin in post-herpetic neuralgia
Author(s):

Rajesh Gupta

DOI:
10.1093/med/9780198834359.003.0069
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 February 2020

The landmark paper discussed in this chapter is ‘Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial’, published by Rowbotham et al. in 1998. In the study, a 4-week initial period of titration of gabapentin (up to a maximum of 3,600 mg) or matching placebo was given, followed by a further 4-week period at the maximum tolerated dose. The primary efficacy measure was change in average daily pain score from start to finish of the treatment, and secondary measures observed were the average daily sleep score, a short-form McGill Pain Questionnaire, the subject’s global impression of change, the investigator-rated clinical global impression of change, the Short Form 36, a quality-of-life questionnaire, and a Profile of Mood States questionnaire. Subjects receiving gabapentin had significant reduction in daily pain scores as well as improvement in secondary measures of pain, although with an increased incidence of side effects.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.